

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of November 2019**

**Commission File Number: 001-38764**

---

**APTORUM GROUP LIMITED**

---

**17<sup>th</sup> Floor, Guangdong Investment Tower  
148 Connaught Road Central  
Hong Kong  
(Address of principal executive offices)**

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

---

On November 14, 2019, Aptorum Group Limited (the “**Company**”) held its 2019 annual general meeting of shareholders (the “**Annual Meeting**”). At the Annual Meeting, the Company’s shareholders voted on 2 proposals. At the beginning of the Annual Meeting, there were 227,113,269 shares in person or by proxy, which represented approximately 98.33% of the voting power of the shares entitled to vote at the Annual Meeting; a quorum was present for the transaction of business.

At the Annual Meeting, the following proposals were voted on:

- To re-elect each of the seven directors identified herein to the Company’s board of directors (the “**Board**”), with such directors to serve until the next annual meeting of shareholders and until his/her respective successor is elected and duly qualified; and

<b>Election of Directors</b>	<b>For</b>	<b>Against</b>	<b>Withhold</b>	<b>Broker Non-Vote</b>
Mr. Ian Huen	227,113,099	170	-	-
Mr. Darren Lui	227,113,099	170	-	-
Dr. Clark Cheng	227,113,099	170	-	-
Mr. Charles Bathurst	227,113,269	0	-	-
Dr. Mirko Scherer	227,113,269	0	-	-
Dr. Justin Wu	227,113,269	0	-	-
Professor Douglas Arner	227,113,099	170	-	-

- To ratify the appointment of Marcum Bernstein & Pinchuk LLP as the Company’s independent auditors for the year ending December 31, 2019, and to authorize the Board of Directors to fix their remuneration.

<b>For</b>	<b>Against</b>	<b>Abstain</b>
227,113,269	0	0

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Aptorum Group Limited**

Date: November 15, 2019

By: /s/ Sabrina Khan

Name: Sabrina Khan

Title: Chief Financial Officer

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
99.1	<a href="#">Press Release Dated November 15, 2019</a>



Aptorum Group Limited  
17/F Guangdong Investment Tower, 148 Connaught Road Central, Hong Kong  
Tel: (852) 2117 6611 • Fax: (852) 2850 7286

## **Aptorum Group Limited Announces Results of 2019 Annual General Meeting**

November 15, 2019

Hong Kong - Aptorum Group Limited (Nasdaq: APM) (“the Company”) a biopharmaceutical company focused on the development of novel therapeutics to address certain global unmet medical needs, announced today the results of its 2019 Annual General Meeting, which was held on November 14, 2019, in Hong Kong.

At the Annual General Meeting, shareholders

- re-elected all of the Company’s current directors, namely Mr. Ian Huen, Mr. Darren Lui, Dr. Clark Cheng, Dr. Justin Wu, Mr. Charles Bathurst, Dr. Mirko Scherer and Professor Douglas Arner as directors of the Company until the Company’s 2020 annual general meeting or until their respective successors are duly appointed and qualified; and
- approved, ratified and confirmed the re-appointment of Marcum Bernstein & Pinchuk LLP as the Company’s independent auditors for the year ending December 31, 2019 and authorized the Board of Directors to fix the remuneration of the auditors.

### **About Aptorum Group Limited**

Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle certain unmet medical needs. Aptorum Group is pursuing therapeutic projects in neurology, infectious diseases, gastroenterology, oncology and other disease areas.

For more information about Aptorum Group, please visit [www.aptorumgroup.com](http://www.aptorumgroup.com).

### **Disclaimer and Forward-Looking Statements**

This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, the company’s anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group’s Form 20-F and other filings that Aptorum Group may make with the SEC in the future. Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

#### **Contact**

Investors:

Tel: +852 2117 6611

Email: [investor.relations@aptorumgroup.com](mailto:investor.relations@aptorumgroup.com)

Media:

Tel: + 852 2117 6611

Email: [info@aptorumgroup.com](mailto:info@aptorumgroup.com)